knowledge -WSS

knowledge

author：explore 2025-10-02 12:01:52 - browse：2139

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Life sciences deals on track to hit lowest point since 2017

hotspot

WSS

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Secretariat’s lessons for human medicine

Medicare Advantage enrollment hits roughly 33.4 million

Peter Marks talks Operation Warp Speed for Rare Diseases

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

European regulators consider appeal over Amylyx ALS drug

hotspot

knowledge

explore

Supreme Court strikes down use of affirmative action

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

After affirmative action ruling, medical educators look to 'holistic review'

Bernie Sanders bashes nonprofit hospitals over their tax breaks

At least 13 dead in Texas as scorching temps continue

Cancer cells are shown to suck energy source from immune cells

Wildfire smoke exposes gaps in outdoor worker protections

Weight loss drugs aren’t covered by Obamacare. That may change

Medicare details structure of new drug price negotiation program

Researchers tackle phage therapy hurdles for wider adoption

hotspot

MD Anderson's Padmanee Sharma responds to research credit suit

MD Anderson's Padmanee Sharma responds to research credit suit

A new drug could help frostbite victims avoid its ravages

Medicare to cover more brain scans related to Alzheimer’s drugs

Researchers tackle phage therapy hurdles for wider adoption

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

hotspot

hotspot

leisure time

focus